Case report. First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462)

Author： Itskovitz-Eldor J  

Publisher： Oxford University Press

ISSN： 1460-2350

Source： Human Reproduction, Vol.13, Iss.2, 1998-02, pp. : 294-295

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

This case report describes the first established pregnancy after the use of gonadotrophin-releasing hormone (GnRH) antagonist, ganirelix (Org 37462); Organon), to prevent a premature luteinizing hormone surge during ovarian hyperstimulation with recombinant human follicle stimulating hormone (rhFSH). The pregnancy progressed normally and ended with the birth of a healthy boy and a girl after an elective Caesarean section at gestational age of 37 weeks. This case illustrates, for the first time, the use of a GnRH antagonist in combination with a pure FSH preparation for ovarian stimulation. Keywords:ganirelix/GnRH antagonist/ovarian stimulation/pregnancy/recombinant human FSH

Related content

A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon®).

By ganirelix dose-finding study group The  

Human Reproduction, Vol. 13, Iss. 11, 1998-11 ,pp. : 3023-3031 (9)

Oxford University Press

Access to resources Recommend Favorite

Infertility. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial

By Borm G.   Mannaerts B.  

Human Reproduction, Vol. 15, Iss. 7, 2000-07 ,pp. : 1490-1498 (9)

Oxford University Press

Access to resources Recommend Favorite

Case report. High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization

By de Jong D  

Human Reproduction, Vol. 13, Iss. 3, 1998-03 ,pp. : 573-575 (3)

Oxford University Press

Access to resources Recommend Favorite

Luteinizing hormone response to gonadotrophin-releasing hormone in normal women undergoing ovulation induction with urinary or recombinant follicle stimulating hormone

By Messinis IE  

Human Reproduction, Vol. 13, Iss. 9, 1998-09 ,pp. : 2415-2420 (6)

Oxford University Press

Access to resources Recommend Favorite

Developmental potential of embryos produced by in-vitro fertilization from gonadotrophin-releasing hormone antagonist-treated macaques stimulated with recombinant human follicle stimulating hormone alone or in combination with luteinizing hormone

By Weston A.M.  

Human Reproduction, Vol. 11, Iss. 3, 1996-03 ,pp. : 608-613 (6)

Oxford University Press

Access to resources Recommend Favorite